Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/37049
Title: | Glabridin attenuates airway inflammation and hyperresponsiveness in a mice model of ovalbumin-induced asthma | Authors: | Doğan, Muhammed Fatih Parlar, A. Cam, S.A. Tosun, E.M. Uysal, F. Arslan, S.O. |
Keywords: | Asthma Glabridin Ovalbumin Plethysmography aluminum hydroxide dexamethasone glabridin immunoglobulin E methacholine ovalbumin protein aerosol animal experiment animal model animal tissue Article asthma body plethysmography breathing rate bronchoalveolar lavage fluid controlled study dose response drug dose comparison drug efficacy drug mechanism drug megadose eosinophil expiratory reserve volume immunoglobulin blood level leukocyte count leukocyte differential count low drug dose lung function lymphocyte male monocyte mouse neutrophil nonhuman ovalbumin-induced airway inflammation peak expiratory flow peak inspiratory flow priority journal respiratory tract allergy tidal volume |
Publisher: | Academic Press | Abstract: | Asthma is an inflammatory disease of the airways of the lungs, which is characterized by airflow obstruction and bronchospasms. Glabridin is a major flavonoid, especially found in root of Glycyrrhiza glabra, and has several pharmacological activities, including antioxidant and anti-inflammatory effects. The anti-asthmatic effect and possible mechanism of glabridin, however, have not been revealed so far. The aim of this study is to investigate the effects and possible mechanisms of glabridin against ovalbumin (OVA)-induced airway hyperresponsiveness (AHR) and inflammation in mice. In male BALB/c mice, asthma was induced by intraperitoneal (i.p) injection of OVA mixed with 2 mg aluminium hydroxide on days 0, 14 and boosted with OVA aerosol challenge on days 21, 22, and 23. Mice were either treated with dexamethasone (i.p, 1 mg/kg) or glabridin (10, 20, and 30 mg/kg) from days 18–23. Pulmonary function parameters such as peak inspiratory flow, peak expiratory flow, tidal volume, expiratory volume, the frequency of breathing, enhanced pause values were evaluated by using whole-body plethysmography. Measurements were performed at baseline and following methacholine (50 mg/mL) challenges. In addition, white blood cells (WBC) count, total protein, and IgE levels were measured in bronchial alveolar lavage fluid (BALF), lung, and serum, respectively. Glabridin (20 or 30 mg/kg) significantly attenuated (p < 0.05) OVA-induced alteration in respiratory parameters. Elevated counts of total WBC, differential WBC (neutrophils, lymphocytes, monocytes, and eosinophils) in BALF and the total protein in lungs and BALF were significantly decreased (p < 0.05) by glabridin (20 or 30 mg/kg). It also significantly attenuated the increased serum IgE levels (p < 0.05). As glabridin reduces the level of serum IgE, the total protein and the count of WBC and improves respiratory function, it may be a novel therapeutic agent in asthma. © 2020 Elsevier Ltd | URI: | https://hdl.handle.net/11499/37049 https://doi.org/10.1016/j.pupt.2020.101936 |
ISSN: | 1094-5539 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
28
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
21
checked on Nov 16, 2024
Page view(s)
42
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.